Regeneron Pharmaceuticals (REGN) presents a bullish thesis supported by a trailing P/E of 20.49, market capitalization of $85.22 billion, TTM revenue of $15.53 billion, and EPS of $40.39. Quarterly revenue growth of 16.7% year-over-year demonstrates resilient demand for its biotechnology portfolio despite a modest -4.5% quarterly earnings contraction. With a low beta of 0.193 and forward P/E of 15.43, the stock offers attractive valuation relative to growth peers in healthcare. Key catalysts include ongoing momentum from flagship products driving 16.7% revenue expansion, analyst consensus target of $840.43 (implying upside from current levels near the 50-day moving average of $737.86), and potential market expansion in biotechnology. Earnings momentum is bolstered by a strong 27.9% profit margin and 14.0% return on equity, positioning the company for continued innovation and pipeline advancement through 2026. Risks encompass regulatory hurdles in drug approvals, competitive pressures from other biotech firms, and macroeconomic headwinds such as interest rate sensitivity affecting R&D funding. Mitigations include a robust 93.7% institutional ownership providing stability, diversified revenue streams, and a conservative balance sheet with book value per share of $316.11. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.